Hikma’ KLOXXADOTM (naloxone hydrochloride) Receives the US FDA’s Approval for the Treatment of Opioid Overdose

 Hikma’ KLOXXADOTM (naloxone hydrochloride) Receives the US FDA’s Approval for the Treatment of Opioid Overdose

Shots:

  • The US FDA approved KLOXXADOTM (Nasal Spray, 8mg) for the emergency treatment of opioid overdose observed in respiratory and/or CNS depression in adult and pediatric patients.
  • In a survey, Narcan (Nasal Spray, 4mg) showed 34% attempted reversals used two or more doses. A separate study published in 2019 showed that the percent of overdose-related emergencies in the US requiring multiple doses of naloxone during 2013-2016 increased to 21% which represented a 43% increase over 4 years
  • KLOXXADOTM contains double the amount of naloxone per spray as Narcan in a ready-to-use nasal spray and it is expected to be available in H2’ 21

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Hikma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post